Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Neuropharmacology of Xylazine and Fentanyl Interactions

Award Number: R21DA063305
ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2026
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

Neuropharmacology of Xylazine and Fentanyl Interactions - ABSTRACT In recent years the 2AR adrenergic receptor (2AR) agonist xylazine has been incorporated in the illicit use of fentanyl, resulting in serious adverse pharmacological effects in users that are poorly understood. The synergistic interactions between mu-opioid receptors and 2AR adrenergic receptors have been long described. Additionally, the ameliorating effects that 2AR adrenergic receptor agonists exert on withdrawal from chronic exposure to mu-opioid receptor agonists is well-established. However, the interaction between xylazine and mu- opioid receptor agonists has been minimally investigated. We have previously extensively evaluated neuropharmacological interactions between clinically used 2AR adrenergic receptor agonists (e.g. clonidine, dexmedetomidine, brimonidine, and moxonidine) and opioid agonists ; we have also defined the mechanism of such interactions both in opioid-naïve rodents and those chronically exposed to opioids. We have also have established a model of fentanyl self-administration in mice. Applying these approaches to evaluation of the combination of xylazine with fentanyl will characterize the neuropharmacology of their interaction. The objective of this application is to test the combination of xylazine and fentanyl in pre-clinical models of analgesia, sedation, opioid tolerance, opioid withdrawal, and opioid self- administration. The central hypothesis of this application is that the pharmacology of the xylazine interaction with opioids is similar to that of the clinically used 2AR agonists. This proposal has two specific aims: i) Define the neuropharmacological mechanisms of xylazine when given alone and in combination with fentanyl. ii) Define the mechanism of the impact of xylazine on oral fentanyl self- administration. At the completion of our research, our expected outcomes are that we will have determined the neuropharmacological interactions of xylazine with fentanyl in well defined measures of analgesia, sedation, opioid analgesic tolerance and withdrawal and opioid self-administration. Our studies will have a positive impact because knowledge gained from pursuit of this program will significantly expand the current understanding of fentanyl and xylazine interactions, which is currently very limited. Such information will inform future approaches aimed at addressing harms associated with the introduction of xylazine into the illicit fentanyl use environment.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $423,500 )
2026	2026	REGENTS OF THE UNIVERSITY OF MINNESOTA	2221 UNIVERSITY AVE SE STE 100	MINNEAPOLIS	MN	55414	HENNEPIN	USA	Drug Use and Addiction Research Programs	000	1	5/22/2026	NEW	$423,500
														Subtotal = $423,500

Grand Total All Awards = $423,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Neuropharmacology of Xylazine and Fentanyl Interactions

Award Number: R21DA063305

ORGANIZATION: NATIONAL INSTITUTE ON DRUG ABUSE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2026

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer